Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Fluorescence Lens Cell

By Drug Discovery Trends Editor | February 25, 2009

MicrocellStarna Scientific Development department has designed and patented a new ultra-micro volume fluorescence lens cell to perform UV/Visible spectrofluorometer analysis on smaller volume samples of typically five microlitres or less.

The ultra-micro cell provides a practical solution for customers where samples cannot be prepared in or diluted to larger volumes. 

Starna’s Type 19FL ultra-micro cell, which avoids the need for dilution, thereby minimizing reagents costs, is well suited to providing analysis in volumes typically handled in molecular biology and forensics applications. 

By offering high sensitivity, even in very small volumes, the Type 19FL ultra-micro cell is also suited to proteomics applications, where the sensitivity of the cell is sufficiently high to measure native fluorescence of proteins prepared in microlitre quantities. The cell design also allows the majority of the sample to be recovered.

The type 19FL ultra-micro lens cell is designed to enable ultra low volume fluorescence measurements in the 5 ul sample volume range. 

The cell allows good quality fluorescence measurements to be achieved using a conventional spectrofluorometer at sample volumes.

Using Far UV non-fluorescence quartz, the Type 19FL Ultra-micro volume fluorescence lens cell, 5 mm path length, can be supplied with a ‘Z’ height of 8.5, 15, and 20mm, and has been designed to make loading and flushing simple, with minimum dead volume. 

www.starna.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50